APA (7th ed.) Citation

Xu, M., Wang, X., Cai, Y., Zhang, H., Yang, H., Liu, C., & Zhang, C. (2011). An engineered superantigen SEC2 exhibits promising antitumor activity and low toxicity. Cancer Immunology, Immunotherapy, 60(5), 705-713. https://doi.org/10.1007/s00262-011-0986-6

Chicago Style (17th ed.) Citation

Xu, Mingkai, Xiaogang Wang, Yongming Cai, Huiwen Zhang, Hongli Yang, Changxiao Liu, and Chenggang Zhang. "An Engineered Superantigen SEC2 Exhibits Promising Antitumor Activity and Low Toxicity." Cancer Immunology, Immunotherapy 60, no. 5 (2011): 705-713. https://doi.org/10.1007/s00262-011-0986-6.

MLA (9th ed.) Citation

Xu, Mingkai, et al. "An Engineered Superantigen SEC2 Exhibits Promising Antitumor Activity and Low Toxicity." Cancer Immunology, Immunotherapy, vol. 60, no. 5, 2011, pp. 705-713, https://doi.org/10.1007/s00262-011-0986-6.